Evidence map›Paper›PMID 28881597›Full record

ArticleOncotarget2017

TGFbeta and miRNA regulation in familial and sporadic breast cancer.

Katia Danza, Simona De Summa, Rosamaria Pinto, Brunella Pilato, Orazio Palumbo, Massimo Carella, Ondina Popescu, Maria Digennaro, Rosanna Lacalamita, Stefania Tommasi

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Katia Danza *IRCCS 'Giovanni Paolo II', Molecular Genetics Laboratory, Bari 70124, Italy.
Simona De Summa *IRCCS 'Giovanni Paolo II', Molecular Genetics Laboratory, Bari 70124, Italy.
Rosamaria PintoIRCCS 'Giovanni Paolo II', Molecular Genetics Laboratory, Bari 70124, Italy.
Brunella PilatoIRCCS 'Giovanni Paolo II', Molecular Genetics Laboratory, Bari 70124, Italy.
Orazio PalumboIRCCS 'Casa Sollievo della Sofferenza', Medical Genetics Unit, San Giovanni Rotondo 71013, Italy.
Massimo CarellaIRCCS 'Casa Sollievo della Sofferenza', Medical Genetics Unit, San Giovanni Rotondo 71013, Italy.
Ondina PopescuIRCCS 'Giovanni Paolo II', Anatomopathology Unit, Bari 70124, Italy.
Maria DigennaroIRCCS 'Giovanni Paolo II', Experimental Medical Oncology Unit, Bari 70124, Italy.
Rosanna LacalamitaIRCCS 'Giovanni Paolo II', Molecular Genetics Laboratory, Bari 70124, Italy.
Stefania TommasiIRCCS 'Giovanni Paolo II', Molecular Genetics Laboratory, Bari 70124, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Tumori Bari · ITCasa Sollievo della Sofferenza · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term 'BRCAness' was introduced to identify sporadic malignant tumors sharing characteristics similar to those germline BRCA-related. Among all mechanisms attributable to BRCA1 expression silencing, a major role has been assigned to microRNAs. MicroRNAs role in familial and sporadic breast cancer has been explored but few data are available about microRNAs involvement in homologous recombination repair control in these breast cancer subgroups. Our aim was to seek microRNAs associated to pathways underlying DNA repair dysfunction in breast cancer according to a family history of the disease. Affymetrix GeneChip microRNA Arrays were used to perform microRNA expression analysis in familial and sporadic breast cancer. Pathway enrichment analysis and microRNA target prediction was carried out using DIANA miRPath v.3 web-based computational tool and miRWalk v.2 database. We analyzed an external gene expression dataset (E-GEOD-49481), including both familial and sporadic breast cancers. For microRNA validation, an independent set of 19 familial and 10 sporadic breast cancers was used. Microarray analysis identified a signature of 28 deregulated miRNAs. For our validation analyses by real time PCR, we focused on miR-92a-1*, miR-1184 and miR-943 because associated to TGF-β signalling pathway, ATM and BRCA1 genes expression. Our results highlighted alterations in miR-92a-1*, miR-1184 and miR-943 expression levels suggesting their involvement in repair of DNA double-strand breaks through TGF-beta pathway control.

Indexed as

ATMBRCA1breast cancermiRNATGF-β pathway

Identifiers

PMID28881597
PMCPMC5584195
OpenAlexW2585517646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.